Predictors of immunomodulator use as early therapy in pediatric Crohn's disease

Journal of Clinical Gastroenterology

Volumn 40, Issue 2, 2006, Pages 145-148

  Jacobstein, Douglas A ^a   Mamula, Petar ^a   Markowitz, Jonathan E ^a   Leonard, Mary ^a   Baldassano, Robert N ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Crohn's disease; Immunomodulators; Inflammatory bowel disease

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; IMMUNOMODULATING AGENT; MERCAPTOPURINE; METHOTREXATE; SERUM ALBUMIN; STEROID; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEMATOCRIT; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PHYSICAL EXAMINATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; BLOOD; CHI SQUARE DISTRIBUTION; NONPARAMETRIC TEST; PREDICTION AND FORECASTING; PRESCHOOL CHILD;

6-MERCAPTOPURINE; ADOLESCENT; AZATHIOPRINE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 33645799518     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000196192.49920.03     Document Type: Article

References (24)

1. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am. 1999;28:445-458.
2. Kugathasan SJ, Judd RH, Hoffmann RG, et al. Epidemiologic and characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143:525-531.
3. Kirschner B. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998;115:813-821.
4. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
5. Markowitz J, Grancher K, Rosa J, et al. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373-380.
6. Cohen MB, Seidman E, Winter H, et al. Controversies in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:203-227.
7. Escher J, Taminiau J, Nieuwenhuis E, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34-58.
8. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266.
9. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-869.
10. Sandborn W. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosprine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
11. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet. 1971;2:1273-1276.
12. Rosenberg JL, Levin B, Wall AJ, et al. A controlled trial of azathioprine in Crohn's disease. Dig Dis. 1975;20:721-726.
13. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
14. Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology. 1974;66:619-622.
15. Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology. 1990;99:1347-1351.
16. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. Lancet. 1971;2:944-947.
17. Markowitz J, Grancher BS, Kohn N, et al. Immunomodulator therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol. 2002;97:928-932.
18. Cuffari C, Theoret Y, Latour S, et al. 6-Mercatopurine metabolism in Crohn's disease correlation with efficacy and toxicity. Gut. 1996;39:401-406.
19. Lewis J, Schwartz J, Lichtenstein G. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018-1024.
20. Present DM, Krumholz SJ, Wolke MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
21. Hildebrand HF, Holmquist B, Kristiansson L, et al. Chronic inflammatory bowel disease in children and adolescents in Sweden. J Pediatr Gastroenterol Nutr. 1991;13:293-297.
22. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
23. Shepanski MA, Markowitz JE, Mamula P, et al. Is an abreviated pediatric Crohn's disease activity index better than the original? J Pediatr Gastroenterol Nutr. 2004;39:68-72.
24. Loonen HJ, Griffiths AM, Merkus MP, et al. A critical assessment of items on the pediatric Crohn's activity index. J Pediatr Gastroenterol Nutr. 2003;36:90-95.